Modelling The Effectiveness of Ibrutinib Versus Physician’s Choice (PC) In Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.249
https://www.valueinhealthjournal.com/article/S1098-3015(17)30583-1/fulltext
Title :
Modelling The Effectiveness of Ibrutinib Versus Physician’s Choice (PC) In Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30583-1&doi=10.1016/j.jval.2017.08.249
First page :
A442
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
232